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Abstract
Inducible activation of nuclear factor-kB (NF-kB) inhibits the apo-
ptotic response to chemotherapy and irradiation. Activation of NF-kB via
phosphorylation of an inhibitor protein IkB leads to degradation of IkB
through the ubiquitin-proteasome pathway. We hypothesized that inacti-
vation of proteasome function will inhibit inducible NF-kB activation,
thereby increasing levels of apoptosis in response to chemotherapy and
enhancing antitumor effects. To assess the effects of proteasome inhibition
on chemotherapy response, human colorectal cancer cells were pretreated
with the dipeptide boronic acid analogue PS-341 (1 mM) prior to exposure
to SN-38, the active metabolite of the topoisomerase I inhibitor, CPT-11.
Inducible activation of NF-kB and growth response were evaluated in
vitro and in vivo. Effects on p53, p21, p27 and apoptosis were determined.
Pretreatment with PS-341 inhibited activation of NF-kB induced by SN-38
and resulted in a significantly higher level of growth inhibition (64–75%)
compared with treatment with PS-341 alone (20–30%) or SN-38 alone
(24–47%; P < 0.002). Combination therapy resulted in a 94% decrease in
tumor size compared with the control group and significantly improved
tumoricidal response to treatment compared with all treatment groups
(P 5 0.02). The level of apoptosis was 80–90% in the treatment group that
received combination treatment compared with treatment with single
agent alone (10%). Proteasome inhibition blocks chemotherapy-induced
NF-kB activation, leading to a dramatic augmentation of chemosensitivity
and enhanced apoptosis. Combining proteasome inhibition with chemo-
therapy has significant potential to overcome the high incidence of chem-
otherapy resistance. Clinical studies are currently in development to
evaluate the role of proteasome inhibition as an important adjuvant to
systemic chemotherapy.
Introduction
The genotoxic effect of conventional anticancer therapy involving
many chemotherapy agents and gamma irradiation results in the
induction of apoptosis in cancer cells (1–3). The ability to inhibit
apoptosis appears to be a principal mechanism by which resistant
cancer cells are protected from chemotherapy and radiation (4–6).
Cellular mechanisms that protect cancer cells against apoptosis in-
clude lack of a functional response mechanism to apoptotic stimuli
(e.g., mutated or deleted p53 tumor suppressor gene), presence of an
inhibitor to apoptosis (e.g., Bcl-2 and IAP3), and the expression of the
multidrug resistance gene (MDR; Refs.7–9). Recently, the inducible
activation of the nuclear transcription factor NF-kB has been reported
to inhibit the apoptotic response to chemotherapy and irradiation (10).
NF-kB, a key transcription factor involved with immune and in-
flammatory responses as well as cell growth, is regulated primarily
through interactions with an inhibitor protein known as IkB (11).
Stimuli that activate NF-kB typically induce the recently identified
IkB kinase (IKK) complex to phosphorylate IkB on NH2-terminal
serines, which leads to ubiquitination and subsequent degradation of
the inhibitor by the proteasome. After IkB degradation, NF-kB trans-
locates to the nucleus, where it regulates genes involved in a variety
of processes, including the suppression of apoptosis (12, 13).
Recently, a gene therapy approach using recombinant adenovirus-
mediated transfer of a modified form of IkBa resulted in significant
augmentation of chemosensitivity and enhanced induction of apopto-
sis in a xenograft tumor model in response to chemotherapy treatment
(14). These findings suggested that NF-kB may represent an impor-
tant molecular target for the purpose of enhancing the sensitivity of
certain cancer cells to apoptotic stimuli. The use of gene therapy to
deliver NF-kB inhibitors is relevant to certain cancers but is limited
when considering widely disseminated metastases.
An alternative strategy for the inhibition of NF-kB activation is
facilitated by inhibition of proteasome function [for a review of the
proteasome function, see Elliott and Adams (15)]. The inhibition of
proteolytic function effectively blocks degradation of cellular proteins
that have undergone ubiquitination, such as IkB. In fact, proteasome
inhibition is a well-established mechanism to block NF-kB in re-
sponse to a variety of stimuli. A clear advantage to this therapeutic
approach is the clinical availability of a systemically administered
small molecule (PS-341, a potent, boronic acid dipeptide that is highly
selective for proteasome inhibition; Ref. 16) that can potentially
inhibit chemotherapy-induced activation of NF-kB and enhance the
apoptotic response to chemotherapy. To evaluate this therapeutic
approach, we hypothesized that inactivation of proteasome function
will inhibit inducible NF-kB activation, resulting in increased levels
of apoptosis in response to chemotherapy and enhanced antitumor
effects in vivo. To test our hypothesis, we used PS-341 to evaluate the
effects of proteasome inhibition on: (a) chemotherapy-induced NF-kB
activation in colorectal cancer cells; (b) the levels of apoptosis after
treatment with chemotherapy; and (c) tumor growth in a xenograft
model treated with chemotherapy.
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Materials and Methods
Chemotherapy Agents. Camptothecin is a specific inhibitor of mamma-
lian DNA topoisomerase I. The camptothecin analogue CPT-11 and its active
metabolite SN-38 were generously provided by J. Malczyn (Pharmacia and
Upjohn Co., Kalamazoo, MI).
Cell Culture. The human colon cancer cell line LOVO was obtained from
ATCC (Rockville, MD). The LOVO cells were grown in F-12 (Ham’s) with
20% FBS. The colon cancer cell lines KM12L4 (generous gifts of J. Fidler,
U. T. M. D. Anderson Cancer Center, Houston, TX), and WiDR (obtained
from ATCC) were grown in MEM with nonessential amino acids (Grand
Island, NY) and 10% FBS. The colon cancer cell line CCD841 (ATCC) was
grown in DMEM with 10% FBS. All media were obtained from Life Tech-
nologies, Inc. (Gaithersburg, MD) and supplemented with 100 mg/ml penicillin
G and 100 mg/ml streptomycin. Cell cultures were maintained at 37°C.
Cell Growth Response. Human colorectal cells, including LOVO,
KM12L4, WiDr, and CCD841, were seeded in six-well plates at 5 3 104
cells/well. Cells were treated with PS-341 24 h after plating at the concentra-
tion of 1 mM for 1 h. The medium was refreshed, and 3 h later, the cells were
treated with SN-38, the active metabolite of CPT-11, at a dose of 10 ng/ml for
LOVO and KM12L4, a dose of 5 ng/ml for WiDr, and at a dose of 0.5n g/ml
for CCD841. PBS, PS-341 alone, and SN-38 alone were used as control
groups. Cells counts were performed daily.
NF-kB Activation Assay. Activation of NF-kB in response to treatment
with chemotherapy and the proteasome inhibitor was determined by the
electrophoretic mobility shift assay as described previously (17). Cells were
cultured by seeding 1 3 106 cells in 100-mm dishes. Once cultures reached
50–70% confluence, they were treated with PS-341 at the dose of 1 mM for 1 h.
Three h later, cells were treated with SN-38 at the dose of 1 mg/ml. Cells were
harvested at 0, 1, 2, and 6 h after treatment with SN-38, and nuclear extracts
were prepared as described previously (17). In brief, cells were harvested and
suspended in hypotonic buffer. The nuclei were pelleted and resuspended in a
low-salt buffer to high-salt buffer. The soluble protein released by centrifuga-
tion was collected and stored at 270°C. The DNA probe used contains an
NF-kB site (underlined) from the H-2kb gene (59-CAGGGCTGGGGATTC-
CCATCTCCACAGTTTCACTTC-39; Ref. 14). Seven mg of nuclear extracts
were preincubated with 1 mg of poly(deoxyinosinic-deoxycytidylic acid) in
binding buffer (10 mM Tris, 50 mM NaCl, 20% glycerol, 0.5 mM EDTA, and
1 mM DTT) for 10 min at room temperature. Approximately 20,000 cpm of
32P-labeled DNA probe were then added and allowed to bind for 15 min. The
complexes were then separated on a 5% polyacrylamide gel and autoradio-
graphed.
Tumoricidal Response to Combination Therapy. The tumor growth re-
sponse to combined treatment with the proteasome inhibitor and CPT-11 was
assessed in a LOVO xenograft model. Tumors were established by injecting
5 3 106 LOVO cells s.c. into the flank of nude mice (NCR nu/nu athymic nude
mice, 5–6 weeks of age, female, and weight of 18–20 g; Taconic, German-
town, NY). Once tumors reached 1-cm diameter in size, the animals received
a tail vein injection of PS-341 at a concentration of 1 mg/kg (the MTD in
mice),4 diluted according to the manufacturer’s instructions in 0.5 ml of PBS.
As a control, 0.5 ml of vehicle alone was administered by tail vein injection.
Four h after administration of PS-341, 33 mg/kg of CPT-11 diluted in 0.5 ml
of PBS were injected by tail vein injection. Control animals received 0.5 ml of
PBS by tail vein injection. Animals were continued on twice weekly treatment,
administered every Monday and Friday. Tumor diameter along two orthogonal
axes was measured every other day to assess response to treatment.
To evaluate the response to increasing dosages of PS-341 when adminis-
tered in combination with CPT-11 (administered at a fixed dose of 33 mg/kg),
treatment groups received 1, 0.5, 0.1, or 0.01 mg/kg of PS-341 diluted in PBS.
A dose of 2.5 mg/kg PS-341 was found to be lethal after a single i.v. injection
in experimental animals (data not shown). Treatment groups received twice
weekly i.v. administration of PS-341 and CPT-11 as described above. Tumor
response was assessed by measuring tumor diameter along two orthogonal
axes every other day.
Assessment of Apoptosis in Vivo. A LOVO xenograft model was used to
evaluate the induction of apoptosis in vivo after systemic treatment with the
proteasome inhibitor PS-341 and CPT-11. Nude mice bearing 1-cm diameter
s.c. tumors were treated with an i.v. injection of PS-341 at a concentration of
1 mg/kg as described above. i.v. injection of vehicle alone was used as a
control. CPT-11 (33 mg/kg) was injected i.v. 4 h after administration of
PS-341. Control animals received 0.5 ml of PBS by tail vein injection. Tumors
were harvested from sacrificed animals 24 h after final treatment and embed-
ded in OCT mounting medium (VWR, Sakura Finetec U.S.A. Inc., Torrance,
CA; lot 1179027). Specimens were then snap-frozen in 2-methylbutane (Al-
drich Chemical Co., Milwaukee, WI) over liquid nitrogen, and stored at
270°C. Four-mm-thick sections were cut and collected on charged and pre-
cleaned microscope slides (Fisher Scientific, Pittsburgh, PA). The presence of
apoptosis, determined by the TUNEL assay was performed using the in situ
cell death detection kit (Boehringer Mannheim Corp., Indianapolis, IN) ac-
cording to manufacturer’s instructions. The apoptotic indices of tumor sections
within areas of viable tumor were estimated from the percentage of cells scored
under a light microscope at 3100.
Western Blot Analysis. Total cell lysates were prepared by homogenizing
the cell pellets in RIPA buffer [25 mM Tris (pH 7.5), 150 mM sodium chloride,
2 mM EDTA, 1 mM dimethyl sulfonyl fluoride, 10 mM sodium orthovanadate,
50 mM b-glycerophosphate, 1% NP40, 5% deoxycholic acid, 1% SDS, and
20% glycerol] containing a mixture of protease inhibitors [25 mg/ml aprotinin,
10 mg/ml leupeptin, and 5 mg/ml pepstatin were combined with 50 mg of
protein extract from cells treated with one of four treatment regimens including
PS-341, SN-38, a combination of PS-341 and SN-38, or PBS (control)]. Four
h after PS-341 treatment, the samples were electrophoresed on 10% SDS-
PAGE gel overlayed with 4% acrylamide stacking gel and transferred to pure
nitrocellulose membrane (0.45 mM pore size; Schleicher & Schuell, Hercules,
CA), followed by blocking with 10% dry milk in 13 Tris-buffered saline
containing 0.1% Tween 20 for 1 h at room temperature. The first antibody P53
(Anti-P53 mouse monoclonal IgG1; Santa Cruz Biotechnology, Santa Cruz
Biotechnology, CA) was used to incubate the blot at room temperature for 1 h
at a dilution of 1:2000. The second antibody was used to incubate, at room
temperature, the dilution of 1:5000 for 30 min. Immunoreactive bands were
visualized by ECL Western blotting analysis system (Amersham Life Sciences,
Buckinghamshire, United Kingdom) and enhanced chemiluminescence. The
ECL system was removed by incubating the blot in ECL strip buffer (100 mM
2-methylethanol, 2% SDS, and 62.5 mM Tris, pH 6.8) at 65°C for 30 min. P27
antibody (mouse monoclonal IgG1; Santa Cruz Biotechnology) was used to
reprobe the blot at the concentration of 1:1000 for 1 h. The secondary antibody
(antimouse IgG-HRP; Promega, Madison, WI) was used at a concentration of
1:2000 for 30 min at room temperature. P21 antibody (goat polyclonal IgG1;
Santa Cruz Biotechnology) at a concentration of 1:1000 was used to reprobe
the blot after removing the ECL system. The secondary antibody used was
antigoat IgG-HRP (Santa Cruz Biotechnology) at a concentration of 1:2000.
Actin, a highly conserved protein expressed in all eukaryotic cells, was used to
quantitate protein loading. The ECL system was removed by incubating the
blot in ECL strip buffer (100 mM 2-methylanol, 2% SDS, and 62 mM Tris, pH
6.8) at 65°C for 30 min. The first antibody, antigoat polyclonal IgG (Santa
Cruz Biotechnology), was used to reprobe the blot at the concentration of
1:500. The second antibody, antigoat IgG-HRP (Santa Cruz Biotechnology)
was used at the concentration of 1:2500 to evaluate the actin expression.
Statistical Analysis. The ANOVA procedure was used to compare cell
growth response and tumor growth response.
Results
Previously, it has been shown that the topoisomerase I inhibitor
CPT-11, or its metabolite SN-38, induces NF-kB activation in cancer
cells in vitro and in tumor models (14, 18). To determine the effect of
proteasome inhibition on the level of NF-kB activation induced by
exposure to chemotherapy in human colorectal cancer cells, cells were
treated with proteasome inhibitor PS-341 prior to chemotherapy treat-
ment (Fig. 1). Activation of NF-kB, assessed by electrophoretic
mobility shift assay, was observed in all cell lines treated with SN-38
alone, with peak levels occurring at either 1 or 2 h after exposure to
SN-38. Pretreatment with PS-341 prior to chemotherapy completely
inhibited activation of NF-kB induced by exposure to SN-38 in all cell
lines tested. Importantly, treatment with PS-341 alone did not result in
activation of NF-kB.4 Personal communication, P. Elliott, Millennium Pharmaceuticals, Inc.
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To determine whether pretreatment with PS-341 would enhance the
anticancer effects of chemotherapy, human colorectal cancer cells
were exposed to PS-341 prior to treatment with SN-38 (Fig. 2).
Treatment with SN-38 or PS-341 alone resulted in 22–30% and
24–47% growth inhibition, respectively, when compared with con-
trols receiving mock treatment. However, when PS-341 was com-
bined with SN-38, cell counts were decreased by 64–75% compared
with untreated controls, resulting in significantly improved growth
inhibition when compared with treatment with PS-341 or SN-38 alone
(P , 0.002; ANOVA). TUNEL staining for the presence of apoptosis
indicates that the markedly increased growth inhibition observed in
the treatment group receiving combined PS-341 and SN-38 is asso-
ciated with a 4-fold increase in the level of apoptosis when compared
with treatment with PS-341 or SN-38 alone (data not shown).
To determine whether the chemosensitivity of tumors could be
enhanced by combining treatment with the administration of the
proteasome inhibitor, a LOVO xenograft model was used (Fig. 3A). In
these experiments, systemic administration of the proteasome inhib-
itor or CPT-11 alone resulted in a 26 and 48% decrease in tumor size,
respectively, when compared with the treatment group receiving mock
treatment with PBS. The treatment group that received combined
systemic administration of the proteasome inhibitor and CPT-11 was
the only group to undergo a true tumoricidal response, in which a
persistent decrease in size of the tumor was observed throughout the
course of treatment. Combined treatment with PS-341 and CPT-11
resulted in a 94% decrease in tumor size, compared with the control
group, and significantly improved tumoricidal response to treatment
when compared with all treatment groups (P 5 0.02; ANOVA).
The ability of PS-341 to enhance chemosensitivity in a dose-
dependent fashion was evaluated in a xenograft model by decreasing
the concentration of the proteasome inhibitor while controlling the
dosage of the CPT-11 (Fig. 3B). As was observed in Fig. 3A, com-
bined treatment of CPT-11 and the MTD (1.0 mg/kg) of PS-341
resulted in a sustained tumoricidal effect in which LOVO tumors
continued to decrease in size throughout the course of therapy. In-
creasing the dosage of PS-341 that was administered in combination
with CPT-11 resulted in a dose-dependent increase in tumor growth
inhibition.
The significantly decreased tumor size that resulted from combined
treatment of PS-341 and CPT-11 may be explained by a growth-
inhibitory effect, an increase in the level of programmed cell death, or
both. Thus, the anticancer effects of combination therapy involving
the proteasome inhibitor PS-341 and SN-38/CPT-11 may be mediated
by regulation of the factors that control the cell cycle and/or through
modulation of the factors that regulate the induction of apoptosis. To
determine whether the combination therapy effects are mediated
through changes in several key cell cycle regulatory factors, we
examined the effects of treatment on the cell cycle regulatory proteins
p53, p21, and p27 in LOVO cells (Fig. 4). Importantly, LOVO cells
are not mutated for p53 but do express oncogenic K-Ras. Treatment
with either SN-38 alone and PS-341 alone resulted in stabilization of
p21, p27, and p53 that was observed at 6 h and persisted until 48 h.
Combination treatment, using PS-341 and SN-38, resulted in a slight
increase in the level of stabilization of p21, p27, and p53 when
compared with single-agent treatment alone. Staining for actin dem-
onstrated equal protein loading in all treatment groups sampled (data
not shown). These data suggest that one potential mechanism of action
of the observed anticancer effects of combination therapy may be
through the stabilization of p53 and the cell cycle regulatory proteins
p21 and p27. This also suggested that the increased apoptosis ob-
served in combination therapy (data not shown) may be attributable to
p53-dependent apoptosis. However, as shown in Fig. 2, an equivalent
reduction in cell number is achieved in either p53 wild-type or mutant
cell lines.
To determine whether apoptosis was increased in the xenograft
Fig. 1. The electrophoresis mobility shift assay was used to evaluate the effect of
PS-341 (1 mM) treatment on the activation of NF-kB induced by treatment with SN-38 (1
mg/ml) in human colorectal cancer cells. Cell cultures were treated with PS-341 or mock
control for 1 h, followed 3 h later by treatment with SN-38. Cells were harvested and
assayed for nuclear translocation of NF-kB at 1, 2, and 6 h after chemotherapy treatment.
Positive control (1) was KM12L4 cells treated for 2 h with 10 ng/ml tumor necrosis
factor-a (a potent activator of NF-kB). The data shown are representative of one of two
independent experiments.
Fig. 2. The effect of proteasome inhibition on the sensitivity of colorectal cancer cell
cultures to treatment with SN-38 was determined. The IC20 (corresponding to the
concentration of SN-38 at which 20% growth inhibition was observed) was determined for
each cell line. The corresponding IC20 was used in each set of experiments for the
individual cell lines, as indicated in parentheses. Cell counts obtained at 96 h after drug
treatment are reported as the means obtained from triplicate experiments; bars, 1 SD.
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tumor model with the combination therapy, tumor sections were
stained for the presence of TUNEL-positive cells after treatment (Fig.
5). The TUNEL-positive tumor cells at 24 h after treatment with
CPT-11 or PS-341 accounted for ;10% of the total number of cells
stained. This relatively low level of apoptosis is not significantly
different from that observed in tumor sections obtained from untreated
controls (data not shown). In comparison, the number of tumor cells
that stained positively for apoptosis was 80–90% in the treatment
group that received combined treatment with PS-341 and CPT-11.
Thus, these findings suggest that the tumoricidal response to com-
bined treatment with PS-341 and CPT-11 appears to result from
markedly increased levels of apoptosis when compared with treatment
with either agent alone.
Discussion
A growing body of evidence suggests that protection of cancer cells
from cell death facilitates tumorigenesis by conveying a selection
advantage to cancer cells, thereby disrupting the homeostatic balance
of cell death and cell growth in favor of cells that use antiapoptotic
survival mechanisms (19). In addition to its role in tumorigenesis,
protection against apoptosis may also play a role in resistance to
conventional treatments, such as chemotherapy and irradiation (19,
20). Survival mechanisms that function by the inhibition of the
apoptotic response may be distinguished by their activity as either
acquired or inducible. Acquired mechanisms of antiapoptosis are
associated with genetic mutations involved in malignant transforma-
tion, such as mutation of the p53 tumor suppressor gene (21), over-
expression of Bcl-2 (8), and overexpression of P-glycoprotein in
multidrug resistance (7). In contrast, inducible mechanisms of anti-
apoptosis, are not directly involved in tumorigenesis and are only
transiently expressed after exposure to genotoxic stimuli such as
anticancer therapies (10, 14).
Recently, we and others have described the inducible antiapoptotic
function of the transcription factor NF-kB as a principle mechanism
by which cancer cells are protected from undergoing programmed cell
death after exposure to tumor necrosis factor-a (10, 22, 23), gamma
irradiation, and some chemotherapy agents (10). We have also re-
ported that protection from apoptosis resulting from inducible NF-kB
activation may be overcome by selective NF-kB inhibition using the
super-repressor IkBa (10, 14, 18). In those studies, infection of tumor
cells with a recombinant adenovirus that expresses a mutated form of
the highly specific NF-kB inhibitor IkBa (super-repressor IkBa)
significantly decreased inducible NF-kB activation in response to
treatment with the topoisomerase I inhibitor CPT-11 in a wide variety
of human colorectal cancer cell lines and the breast cancer cell line
MCF-7 (18). The inhibition of inducible NF-kB resulted in enhanced
chemosensitivity in vitro and in xenograft models of both colorectal
cancer and sarcoma (14, 18). It was also demonstrated that the
enhanced response to chemotherapy was associated with markedly
increased levels of apoptosis after combination treatment (14, 18).
The mechanisms responsible for the antiapoptotic effects of NF-kB
activation after exposure to chemotherapy and gamma irradiation
Fig. 3. The effects of combination therapy using the proteasome inhibitor PS-341 and
CPT-11 were assessed in a xenograft model. One-cm-diameter LOVO tumors were grown
in the flanks of nude mice. The tumoricidal effects of systemic treatment was assessed (A)
after pretreatment with PS-341 (1 mg/kg i.v. bolus injection) or vehicle alone, followed by
i.v. bolus administration of CPT-11 (33 mg/kg) or vehicle. Treatment was administered
biweekly (Monday and Thursday), and tumor diameter along two orthogonal axes was
recorded every other day. Tumor volume was calculated by assuming a spherical shape of
the tumor, using the formula: volume 5 4/3 pr3, where r is 1⁄2 (mean diameter of the
tumor), and recorded as the means for each treatment group (n 5 8–10); bars, SE. The
dose response to increasing concentrations of PS-341 when used in combination with a
fixed dosage of CPT-11 (33 mg/kg) was assessed in a LOVO xenograft model (B). The
tumoricidal response to different concentrations of PS-341, including the MTD (1 mg/kg)
in nude mice, was determined by pretreatment with an i.v. bolus administration of PS-341,
followed by an i.v. bolus administration of CPT-11. Treatment was administered bi-
weekly, and tumor diameter along two orthogonal axes was recorded every other day
(n 5 8–10). Tumor volume was calculated as described above.
Fig. 4. Stabilization of cellular proteins mediated by combination therapy using
proteasome inhibitor PS-341 and SN-38. A, Western blots of p53 in LOVO cells at 0, 6,
24, and 48 h after treatment with SN-38. The treatment group labeled SN-38 was
pretreated with PBS alone prior to chemotherapy treatment; treatment group PS-341 was
pretreated with PS-341 4 h prior to mock treatment; treatment group PS341/SN-38 was
pretreated with PS-341 4 h prior to treatment with SN-38. Immunoblot analysis was used
to detect p21 (B) and p27 (C) from protein obtained from whole cell lysates using LOVO
cells treated in a similar fashion to that described above.
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have not been fully elucidated. However, it is likely that downstream
gene targets that are NF-kB regulated, such as the IAP proteins
c-IAP1 and c-IAP2, are involved in this inducible survival mech-
anism (9).
Several methods of inhibiting NF-kB activation are currently under
investigation in preclinical studies in our laboratory. One of the first
and most effective methods of NF-kB inhibition uses recombinant
adenovirus-mediated overexpression of the IkBa gene, described pre-
viously. However, the clinical feasibility of gene therapy approaches
for inhibiting NF-kB are currently limited by the requisite intratu-
moral delivery of the recombinant virus that expresses the NF-kB
inhibitor. Alternatively, a systemic means of inhibiting NF-kB may be
applicable in the treatment of widely disseminated metastatic disease.
In this setting, i.v. administered agents that block the antiapoptotic
response mediated by chemotherapy-induced NF-kB activation in
tumor cells may enhance the response of metastatic disease to con-
ventional drug treatment. To examine the potential role of systemic
NF-kB inhibition to enhance chemosensitivity of human cancer cells,
we have selected the proteasome inhibitor PS-341, which has been
shown to block NF-kB activation through stabilization of IkBa, to
combine with the chemotherapy agent SN-38/CPT-11.
The ubiquitin-proteasome pathway (specifically, the 26S protea-
some) is the principle mechanism by which cellular proteins, includ-
ing ubiquitinated IkBa, are degraded (24–26). Inhibition of the ubiq-
uitin-proteasome pathway results in dysregulation of cellular proteins
involved in cell cycle control, promotion of tumor growth, and induc-
tion of apoptosis (16). Recently, a novel class of anticancer agents
called proteasome inhibitors that yield effective anticancer responses
both in vitro and in vivo have been introduced into the treatment of
malignancy (16, 27). The dipeptide boronic acid analogue PS-341,
used in these experiments, inhibits the chymotryptic activity of the
proteasome in a potent, reversible, and selective manner (16). Protea-
some inhibition using this compound has demonstrated significant
cytotoxic activity against a range of human tumor cell lines that
comprise the National Cancer Institute in vitro screen and is well
tolerated in preclinical animal studies and in Phase I clinical trials
(16). The ability of proteasome inhibitors to regulate NF-kB activa-
tion has led many to speculate that these new compounds may have
important clinical implications in the management of both inflamma-
tory disease and malignancy (28).
This report addresses the issue of whether pretreatment of cancer
cells with PS-341 can effectively block the activation of NF-kB that
is induced by exposure to SN-38/CPT-11. As a second objective, we
have sought to determine whether NF-kB inhibition using PS-341
may augment the sensitivity of tumor cells to chemotherapy. Similar
to the findings we reported using the super-repressor IkBa (14, 18),
proteasome inhibition using PS-341 potently blocked the early acti-
vation of NF-kB at 2 h after chemotherapy treatment. In addition,
combining proteasome inhibition with chemotherapy treatment re-
sulted in a significant anticancer effect compared with treatment with
single agent alone. TUNEL assays, performed to determine whether
this increased anticancer effect from combination treatment was at-
tributable in part to regulation of apoptosis, demonstrated markedly
increased levels of apoptosis compared with single agent treatment
alone. This observed response is comparable with the response ob-
served when NF-kB was selectively inhibited using the super-repres-
sor IkBa in our previous reports (14, 18).
Our findings suggest that the enhanced anticancer effects, observed
when PS-341 is combined with chemotherapy, are attributable to
inhibition of inducible NF-kB activation. However, potentially other
cell cycle regulatory processes and apoptotic response mechanisms
impacted by proteasome inhibition play a contributing role:
(a) Proteasome inhibition may result in prolonged binding of the
camptothecin to the topoisomerase-1 enzyme in a complex that under
physiological conditions would be degraded by the proteasome (29).
Enhanced sensitivity to SN-38/CPT-11 when a proteasome inhibitor is
coadministered may therefore result in part from the impaired metab-
olism and longer half-life of the topoisomerase 1-camptothecin com-
plex, resulting from impaired proteasome function. The addition of
the proteasome inhibitor to chemotherapy would thereby effectively
increase the duration of activity of the SN-38/CPT-11.
(b) The findings that p21, p27, and p53 are stabilized by chemo-
therapy or PS-341 treatment suggest that stabilization of these key cell
cycle regulatory proteins may be involved in the antitumor effects of
these molecules when used alone or in combination. The ability to
enhance chemosensitivity by proteasome inhibition, however, was
observed in cells expressing both wild-type p53 (CCD841 and
LOVO), mutant p53 (KM12L4 and WiDR), and Bcl-2 (KM12L4),
suggesting that inhibition of chemotherapy-induced NF-kB activation
using proteasome inhibition may occur independently of the func-
tional status of p53 in colorectal cancer cell lines.
Although a variety of mechanisms in addition to inhibition of
NF-kB may potentially contribute to the efficacy of combination
therapy using PS-341 and SN-38/CPT-11, additional studies will be
necessary to further elucidate this potentially complex response. Fur-
thermore, the ability of proteasome inhibition to enhance the sensi-
Fig. 5. Representative photomicrographs dem-
onstrating TUNEL staining of LOVO tumor sec-
tions after treatment with CPT-11 (left), PS-341
(center), and combination PS-341 and CPT-11
(right). Tumors were harvested 24 h after final
treatment.
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tivity of other genotoxic anticancer therapies without increasing tox-
icity in preclinical animal studies warrants further evaluation and is
the focus of ongoing studies in our laboratory. Nevertheless, the
dramatic augmentation of sensitivity to SN-38/CPT-11 observed both
in vitro and in vivo reported here has significant potential to overcome
the relatively high incidence of chemotherapy resistance seen in
patients with metastatic disease. Clinical studies to evaluate the role of
proteasome inhibition as an important adjuvant to systemic chemo-
therapy are currently in development.
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